Search
BullFrog AI Holdings, Inc.
BFRGAdd to Watchlist
0.700USD
-0.009-1.24%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
12.91MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.24%
5 Days
+6.87%
1 Month
-9.07%
6 Months
-20.48%
Year to Date
-20.72%
1 Year
-57.06%
Key Figures
0.710Open
0.710High
161.60KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.88%Turnover Ratio
0.709Prev. Close
0.640Low
59.58KTurnover
LossP/E Static
2.64P/B
0.00%Div Yield TTM
-126.21%ROA
2.04052wk High
1.67Volume Ratio
-7.04MNet Profit
18.45MShares
-0.5434EPS TTM
--Beta
-149.35%ROE
0.42552wk Low
9.88%Amplitude
18.76%Gross Margin
12.91MMarket Cap
-1.27Reward/Risk
6.24%Risk Rate
TradingKey Stock Score of BullFrog AI Holdings, Inc.
Currency: USD Updated: 2026-07-02Key Insights
BullFrog AI Holdings, Inc.'s fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 216 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BullFrog AI Holdings, Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
BullFrog AI Holdings, Inc. Highlights
StrengthsRisks
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 79.49% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 116.67K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 116.67K.
Overvalued
The company’s latest PE is -1.29, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 629.79K shares, decreasing 48.62% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 29.96K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.88.
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
BullFrog AI Holdings, Inc. News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BullFrog AI Holdings, Inc. Info
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
Ticker SymbolBFRG
CompanyBullFrog AI Holdings, Inc.
CEOSingh (Vininder)
Websitehttps://www.bullfrogai.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of BullFrog AI Holdings, Inc. (BFRG)?
The current price of BullFrog AI Holdings, Inc. (BFRG) is 0.70.
What is the symbol of BullFrog AI Holdings, Inc.?
The ticker symbol of BullFrog AI Holdings, Inc. is BFRG.
What is the 52-week high of BullFrog AI Holdings, Inc.?
The 52-week high of BullFrog AI Holdings, Inc. is 2.04.
What is the 52-week low of BullFrog AI Holdings, Inc.?
The 52-week low of BullFrog AI Holdings, Inc. is 0.43.
What is the market capitalization of BullFrog AI Holdings, Inc.?
The market capitalization of BullFrog AI Holdings, Inc. is 12.91M.
What is the Earnings Per Share (EPS TTM) of BullFrog AI Holdings, Inc. (BFRG)?
The Earnings Per Share (EPS TTM) of BullFrog AI Holdings, Inc. (BFRG) is -0.63.